Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
427
-
Total 13F shares, excl. options
-
81.6M
-
Shares change
-
+2.04M
-
Total reported value, excl. options
-
$5.17B
-
Value change
-
+$153M
-
Put/Call ratio
-
0.59
-
Number of buys
-
262
-
Number of sells
-
-157
-
Price
-
$63.31
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q3 2024
534 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 427 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.6M shares
of 112M outstanding shares and own 72.72% of the company stock.
Largest 10 shareholders include FMR LLC (16.6M shares), VANGUARD GROUP INC (10.2M shares), BlackRock, Inc. (5.38M shares), STATE STREET CORP (4.67M shares), JPMORGAN CHASE & CO (2.12M shares), MORGAN STANLEY (1.87M shares), GEODE CAPITAL MANAGEMENT, LLC (1.86M shares), PERCEPTIVE ADVISORS LLC (1.7M shares), CITADEL ADVISORS LLC (1.47M shares), and Pictet Asset Management Holding SA (1.36M shares).
This table shows the top 427 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.